Clinical Trials Logo

Colchicine Adverse Reaction clinical trials

View clinical trials related to Colchicine Adverse Reaction.

Filter by:
  • None
  • Page 1

NCT ID: NCT05168137 Recruiting - HIV Infections Clinical Trials

Efficacy and Safety of Low-Dose Colchicine on Surrogate Markers of Cardiovascular Events in People Living With HIV Receiving Antiretroviral Therapy

Start date: February 1, 2020
Phase: Phase 4
Study type: Interventional

In a double-blind, randomized controlled trial, we assigned PLWH receiving ART without a history of cardiovascular events to received colchicine 0.6 mg once daily or placebo. The primary endpoint was the mean difference of hs-CRP, IL-6, and IL-1 Ra levels at three and six months. The secondary endpoint was to access safety outcomes.

NCT ID: NCT05006001 Active, not recruiting - Gout Clinical Trials

Evaluation of Colchicine and Nonsteroidal Anti-inflammatory Drug Combination Therapy and Renal Function in Gout Patients

Start date: January 1, 2012
Phase:
Study type: Observational

Our findings are expected to provide real-world evidence of the renal-adverse effects of colchicine and NSAIDs combination therapy in patients with gout, which will guide healthcare professions in optimizing gout treatment regimens and evaluating risks of renal impairment.

NCT ID: NCT04224545 Completed - Clinical trials for Atrial Fibrillation New Onset

COlchicine in Cardiac Surgery

COCS
Start date: December 23, 2019
Phase: Phase 4
Study type: Interventional

Postoperative atrial fibrillation (POAF) is a major complication of cardiac surgery, which could lead to high morbidity and mortality, increase duration of hospital stay and increase the cost of treatment. Colchicine possesses both anti-inflammatory and sympatholytic properties, so it has been studied to prevent POAF. The ACC/AHA guidelines for colchicine contain a class IIB recommendation, but the ESC guidelines do not recommend this drug. More researches are needed to focus on reducing of side effects by optimizing the colchicine regimen to reduce the incidence of gastrointestinal side effects. It is believed that further research is needed to investigate the efficacy and safety of colchicine in these conditions. This research is aimed to study the effectiveness of short-term administration of the drug.

NCT ID: NCT03015831 Terminated - Atrial Fibrillation Clinical Trials

Effect of Low Dose ColchiciNe on the InciDence of POAF

END-AFLD
Start date: October 2, 2017
Phase: Phase 3
Study type: Interventional

The prior End-AF study by the same group showed that 1 mg of colchicine didn't decrease the incidence of AF after cardiac surgery. The current study, End-AF Low Dose Study, will test 0.5 mg colchicine vs. placebo in preventing AF after cardiac surgery.